CN114560913A - 一种用于癌症治疗的多肽探针及其制备方法和应用 - Google Patents
一种用于癌症治疗的多肽探针及其制备方法和应用 Download PDFInfo
- Publication number
- CN114560913A CN114560913A CN202111537634.7A CN202111537634A CN114560913A CN 114560913 A CN114560913 A CN 114560913A CN 202111537634 A CN202111537634 A CN 202111537634A CN 114560913 A CN114560913 A CN 114560913A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- compound
- probe
- formula
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 119
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 111
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 111
- 239000000523 sample Substances 0.000 title claims abstract description 80
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 46
- 201000011510 cancer Diseases 0.000 title claims abstract description 30
- 238000002360 preparation method Methods 0.000 title claims abstract description 21
- 230000000694 effects Effects 0.000 claims abstract description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 25
- 150000001875 compounds Chemical class 0.000 claims description 25
- 239000008055 phosphate buffer solution Substances 0.000 claims description 23
- 239000000243 solution Substances 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 19
- 229940125904 compound 1 Drugs 0.000 claims description 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 13
- 230000002776 aggregation Effects 0.000 claims description 11
- 238000004220 aggregation Methods 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims description 6
- PZBFGYYEXUXCOF-UHFFFAOYSA-N TCEP Chemical compound OC(=O)CCP(CCC(O)=O)CCC(O)=O PZBFGYYEXUXCOF-UHFFFAOYSA-N 0.000 claims description 6
- NKNDPYCGAZPOFS-UHFFFAOYSA-M copper(i) bromide Chemical compound Br[Cu] NKNDPYCGAZPOFS-UHFFFAOYSA-M 0.000 claims description 6
- 239000007850 fluorescent dye Substances 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 235000010378 sodium ascorbate Nutrition 0.000 claims description 6
- 229960005055 sodium ascorbate Drugs 0.000 claims description 6
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 claims description 6
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 claims description 6
- 239000003638 chemical reducing agent Substances 0.000 claims description 4
- 239000003054 catalyst Substances 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 abstract description 59
- 210000003712 lysosome Anatomy 0.000 abstract description 27
- 230000001868 lysosomic effect Effects 0.000 abstract description 27
- 230000006395 clathrin-mediated endocytosis Effects 0.000 abstract description 8
- 230000012202 endocytosis Effects 0.000 abstract description 8
- 238000002428 photodynamic therapy Methods 0.000 abstract description 6
- 230000001404 mediated effect Effects 0.000 abstract description 5
- 210000003470 mitochondria Anatomy 0.000 abstract description 5
- 230000000638 stimulation Effects 0.000 abstract description 5
- 239000002121 nanofiber Substances 0.000 abstract description 4
- 102000006478 Protein Phosphatase 2 Human genes 0.000 abstract description 3
- 108010058956 Protein Phosphatase 2 Proteins 0.000 abstract description 3
- 230000002829 reductive effect Effects 0.000 abstract description 3
- 230000002121 endocytic effect Effects 0.000 abstract description 2
- 238000011275 oncology therapy Methods 0.000 abstract description 2
- 230000037361 pathway Effects 0.000 abstract description 2
- 102000000424 Matrix Metalloproteinase 2 Human genes 0.000 abstract 1
- 108010016165 Matrix Metalloproteinase 2 Proteins 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 25
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 25
- 229940079593 drug Drugs 0.000 description 15
- 238000002474 experimental method Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 201000007983 brain glioma Diseases 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 230000001225 therapeutic effect Effects 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 238000003384 imaging method Methods 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 230000005540 biological transmission Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 208000032612 Glial tumor Diseases 0.000 description 4
- 206010018338 Glioma Diseases 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 230000004651 endocytosis pathway Effects 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000001700 mitochondrial membrane Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000003910 polypeptide antibiotic agent Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 102000044503 Antimicrobial Peptides Human genes 0.000 description 3
- 108700042778 Antimicrobial Peptides Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000010226 confocal imaging Methods 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 239000011261 inert gas Substances 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 230000002132 lysosomal effect Effects 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000012634 optical imaging Methods 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 239000008223 sterile water Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 229930183931 Filipin Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000003917 TEM image Methods 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 230000008045 co-localization Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- IMQSIXYSKPIGPD-NKYUYKLDSA-N filipin Chemical compound CCCCC[C@H](O)[C@@H]1[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@@H](O)C[C@H](O)\C(C)=C\C=C\C=C\C=C\C=C\[C@H](O)[C@@H](C)OC1=O IMQSIXYSKPIGPD-NKYUYKLDSA-N 0.000 description 2
- 229950000152 filipin Drugs 0.000 description 2
- IMQSIXYSKPIGPD-UHFFFAOYSA-N filipin III Natural products CCCCCC(O)C1C(O)CC(O)CC(O)CC(O)CC(O)CC(O)CC(O)C(C)=CC=CC=CC=CC=CC(O)C(C)OC1=O IMQSIXYSKPIGPD-UHFFFAOYSA-N 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 125000005439 maleimidyl group Chemical group C1(C=CC(N1*)=O)=O 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- DNUYOWCKBJFOGS-UHFFFAOYSA-N 2-[[10-(2,2-dicarboxyethyl)anthracen-9-yl]methyl]propanedioic acid Chemical compound C1=CC=C2C(CC(C(=O)O)C(O)=O)=C(C=CC=C3)C3=C(CC(C(O)=O)C(O)=O)C2=C1 DNUYOWCKBJFOGS-UHFFFAOYSA-N 0.000 description 1
- 238000011729 BALB/c nude mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000020313 Cell-Penetrating Peptides Human genes 0.000 description 1
- 108010051109 Cell-Penetrating Peptides Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000006845 Michael addition reaction Methods 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- ABUBSBSOTTXVPV-UHFFFAOYSA-H [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O Chemical compound [U+6].CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O.CC([O-])=O ABUBSBSOTTXVPV-UHFFFAOYSA-H 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 229920006317 cationic polymer Polymers 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000000942 confocal micrograph Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000000295 emission spectrum Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- QDERNBXNXJCIQK-UHFFFAOYSA-N ethylisopropylamiloride Chemical compound CCN(C(C)C)C1=NC(N)=C(C(=O)N=C(N)N)N=C1Cl QDERNBXNXJCIQK-UHFFFAOYSA-N 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000004896 high resolution mass spectrometry Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000004941 influx Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- ZPIRTVJRHUMMOI-UHFFFAOYSA-N octoxybenzene Chemical compound CCCCCCCCOC1=CC=CC=C1 ZPIRTVJRHUMMOI-UHFFFAOYSA-N 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000003504 photosensitizing agent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- -1 polyoxyethylene dodecyl ether Polymers 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000007142 ring opening reaction Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940043263 traditional drug Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000004627 transmission electron microscopy Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111537634.7A CN114560913A (zh) | 2021-12-15 | 2021-12-15 | 一种用于癌症治疗的多肽探针及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111537634.7A CN114560913A (zh) | 2021-12-15 | 2021-12-15 | 一种用于癌症治疗的多肽探针及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114560913A true CN114560913A (zh) | 2022-05-31 |
Family
ID=81711703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111537634.7A Pending CN114560913A (zh) | 2021-12-15 | 2021-12-15 | 一种用于癌症治疗的多肽探针及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114560913A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115925803A (zh) * | 2022-07-01 | 2023-04-07 | 华中科技大学 | 一种点亮型GPx4荧光分子探针及其应用 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789542A (en) * | 1994-04-22 | 1998-08-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Amphipathic peptides |
US20180244720A1 (en) * | 2015-04-23 | 2018-08-30 | Sanford Burnham Prebys Medical Discovery Institute | Targeted delivery system and methods of use therefor |
CN108815537A (zh) * | 2018-06-08 | 2018-11-16 | 华中科技大学 | 一种肿瘤细胞靶向特异性荧光探针及其制备方法与应用 |
CN113185578A (zh) * | 2021-04-25 | 2021-07-30 | 中国地质大学(武汉) | 一种模块化多肽-aie探针mp及其合成方法、包含其的试剂盒 |
CN113429460A (zh) * | 2021-06-18 | 2021-09-24 | 中国地质大学(武汉) | 一种用于细胞膜成像的荧光探针及其制备方法和应用 |
US11191804B2 (en) * | 2018-01-09 | 2021-12-07 | Fujita Academy | Cytocidal agent |
CN116082464A (zh) * | 2023-01-16 | 2023-05-09 | 中国地质大学(武汉) | 作用于肿瘤细胞膜的多肽探针及其制备方法和应用 |
CN116199748A (zh) * | 2023-01-16 | 2023-06-02 | 中国地质大学(武汉) | 多肽荧光探针及其在检测活细胞内聚集蛋白中的应用 |
CN116338205A (zh) * | 2023-02-23 | 2023-06-27 | 中国地质大学(武汉) | Pkk-tpp多肽探针在区分细胞周期不同阶段中的新应用 |
-
2021
- 2021-12-15 CN CN202111537634.7A patent/CN114560913A/zh active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5789542A (en) * | 1994-04-22 | 1998-08-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Amphipathic peptides |
US20180244720A1 (en) * | 2015-04-23 | 2018-08-30 | Sanford Burnham Prebys Medical Discovery Institute | Targeted delivery system and methods of use therefor |
US11191804B2 (en) * | 2018-01-09 | 2021-12-07 | Fujita Academy | Cytocidal agent |
CN108815537A (zh) * | 2018-06-08 | 2018-11-16 | 华中科技大学 | 一种肿瘤细胞靶向特异性荧光探针及其制备方法与应用 |
CN113185578A (zh) * | 2021-04-25 | 2021-07-30 | 中国地质大学(武汉) | 一种模块化多肽-aie探针mp及其合成方法、包含其的试剂盒 |
CN113429460A (zh) * | 2021-06-18 | 2021-09-24 | 中国地质大学(武汉) | 一种用于细胞膜成像的荧光探针及其制备方法和应用 |
CN116082464A (zh) * | 2023-01-16 | 2023-05-09 | 中国地质大学(武汉) | 作用于肿瘤细胞膜的多肽探针及其制备方法和应用 |
CN116199748A (zh) * | 2023-01-16 | 2023-06-02 | 中国地质大学(武汉) | 多肽荧光探针及其在检测活细胞内聚集蛋白中的应用 |
CN116338205A (zh) * | 2023-02-23 | 2023-06-27 | 中国地质大学(武汉) | Pkk-tpp多肽探针在区分细胞周期不同阶段中的新应用 |
Non-Patent Citations (6)
Title |
---|
AGEMY L, ET AL.: "Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma", 《PROC NATL ACAD SCI U S A》, vol. 108, no. 42, pages 17450 * |
JUN DAI. ET AL.: "Modular Peptide Probe for Pre/Intra/Postoperative Therapeutic to Reduce Recurrence in Ovarian Cancer", 《ACS NANO》, vol. 14, no. 11, pages 14700 * |
TANAKA, A. ET AL: "Cancer cell death induced by the intracellular self-assembly of an enzyme-responsive supramolecular gelator", 《J. AM. CHEM. SOC》, vol. 137, pages 771 * |
YANG J, ET AL: "Endocytosis Pathway Self-Regulation for Precise Image-Guided Therapy through an Enzyme-Responsive Modular Peptide Probe", 《ANALYTICAL CHEMISTRY》, vol. 94, no. 22 * |
房玉潇等: "肿瘤微环境响应型纳米药物递送系统在肿瘤治疗中的研究进展", 《生命的化学》, vol. 40, no. 10 * |
杨聚梁: "基于聚集诱导发光的模块化多肽探针的设计及其在癌症治疗中的应用研究", 《中国博士学位论文全文数据库 工程科技I辑》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115925803A (zh) * | 2022-07-01 | 2023-04-07 | 华中科技大学 | 一种点亮型GPx4荧光分子探针及其应用 |
CN115925803B (zh) * | 2022-07-01 | 2024-05-14 | 华中科技大学 | 一种点亮型GPx4荧光分子探针及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Ding et al. | Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy | |
Liang et al. | Core-shell structured upconversion nanocrystal-dendrimer composite as a carrier for mitochondria targeting and catalase enhanced anti-cancer photodynamic therapy | |
Soukos et al. | The effect of charge on cellular uptake and phototoxicity of polylysine Chlorine6Conjugates | |
Chen et al. | Dimeric BODIPY-loaded liposomes for dual hypoxia marker imaging and activatable photodynamic therapy against tumors | |
CN110755407B (zh) | 一种二氧化锰/葡萄糖氧化酶@透明质酸复合抗癌材料及其制备和应用 | |
Wang et al. | Tumor‐microenvironment‐activated in situ self‐assembly of sequentially responsive biopolymer for targeted photodynamic therapy | |
Liu et al. | H 2 O 2-activated oxidative stress amplifier capable of GSH scavenging for enhancing tumor photodynamic therapy | |
WO2023061194A1 (zh) | 一种光敏剂分子及其在提高肿瘤滞留时间增强大体积肿瘤治疗中的应用 | |
CN113633625B (zh) | 一种杂膜负载氧化磷酸化抑制剂的纳米药物及其制备方法 | |
Kato et al. | Electron donors rather than reactive oxygen species needed for therapeutic photochemical reaction of near-infrared photoimmunotherapy | |
Zhang et al. | Cisplatin and quantum dots encapsulated in liposomes as multifunctional nanocarriers for theranostic use in brain and skin | |
Yin et al. | Cleavable collagenase-assistant nanosonosensitizer for tumor penetration and sonodynamic therapy | |
Dong et al. | Synergetic lethal energy depletion initiated by cancer cell membrane camouflaged nano-inhibitor for cancer therapy | |
CN114560913A (zh) | 一种用于癌症治疗的多肽探针及其制备方法和应用 | |
Dai et al. | A Chimeric Peptide Logic Gate for Orthogonal Stimuli‐Triggered Precise Tumor Therapy | |
He et al. | D‐type neuropeptide decorated AIEgen/RENP hybrid nanoprobes with light‐driven ROS generation ability for NIR‐II fluorescence imaging‐guided through‐skull photodynamic therapy of gliomas | |
Yu et al. | Hot-band absorption assisted single-photon frequency upconversion luminescent nanophotosensitizer for 808 nm light triggered photodynamic immunotherapy of cancer | |
CN113546042A (zh) | 一种基于切伦科夫效应的酸响应纳米胶束及其制备方法和应用 | |
Li et al. | Nuclear PARP1‐Targeted Photosensitizer as a Dual‐Mode DNA‐Damaging Agent and Immune Activator for Tumor Ablation | |
Li et al. | Palliating the escalated post-PDT tumor hypoxia with a dual cascade oxygenation nanocomplex | |
CN112939905B (zh) | 一种具有聚集诱导发光性质的化合物及其制备方法和应用 | |
CN111821436A (zh) | 肿瘤原位产氧增敏光动力疗效的靶向穿透型纳米诊疗复合物及其构建方法 | |
Adriouach et al. | Squalene-PEG: Pyropheophorbide-a nanoconstructs for tumor theranostics | |
Chen et al. | Theranostic nanosystem mediating cascade catalytic reactions for effective immunotherapy of highly immunosuppressive and poorly penetrable pancreatic tumor | |
Meng et al. | Short-wavelength aggregation-induced emission photosensitizers for solid tumor therapy: Enhanced with white-light fiber optic |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20221216 Address after: Baogu Innovation and Entrepreneurship Center, China University of Geosciences (Wuhan), No. 388, Lumo Road, Hongshan District, Wuhan, 430000, Hubei Applicant after: Wuhan in the big asset management Co.,Ltd. Address before: 430000 Lu Mill Road, Hongshan District, Wuhan, Hubei Province, No. 388 Applicant before: CHINA University OF GEOSCIENCES (WUHAN CITY) |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20230306 Address after: 274000 Room 513, Floor 5, National Science and Technology Business Incubator, Jiantai Road, Nancheng Sub-district Office, Shan County, Heze City, Shandong Province Applicant after: Shandong Leize Biotechnology Co.,Ltd. Address before: Baogu Innovation and Entrepreneurship Center, China University of Geosciences (Wuhan), No. 388, Lumo Road, Hongshan District, Wuhan, 430000, Hubei Applicant before: Wuhan in the big asset management Co.,Ltd. |
|
TA01 | Transfer of patent application right |